The Backlog Grew 40%, The Stock Fell Anyway

80% of the world's cancer centers use this company's equipment.

Mirion Technologies (MIR) makes radiation detection and monitoring systems. Their gear protects workers in over 130 countries, sits inside nuclear plants and hospitals, and got picked for NASA's Artemis II mission this year to track radiation exposure on the astronauts.

None of that is optional spending. When a nuclear facility needs radiation monitoring, it needs radiation monitoring, and the regulations don’t care what the economy is doing.

So, why is the stock down?

They missed on revenue last quarter, and the market took the shares from $16.79 to $14.74.

Then look at what got buried in that reaction:

Revenue was up 19.7% year over year and earnings beat by 17%. The backlog, meaning work already ordered and not yet delivered, grew nearly 40% to over $1.1 billion.

So, the orders are there, and what slipped was the timing of when they turn into revenue.

That’s a completely different problem from customers going away.

Since then, the board approved a new $250 million buyback on August 31st, running through 2031. They’d already bought back about 2.6 million shares for roughly $40 million in the third quarter, substantially finishing the previous program.

Insiders have been buying alongside them.

Regulatory barriers keep new competitors out, because you can’t enter this business without certifications that take years to obtain.

The product line is broad enough that customers buy the whole system instead of one piece.